BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2689 related articles for article (PubMed ID: 25424347)

  • 21. MicroRNA-1296 inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting SRPK1-mediated PI3K/AKT pathway.
    Xu Q; Liu X; Liu Z; Zhou Z; Wang Y; Tu J; Li L; Bao H; Yang L; Tu K
    Mol Cancer; 2017 Jun; 16(1):103. PubMed ID: 28606154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Co-targeting of IGF1R/mTOR pathway by miR-497 and miR-99a impairs hepatocellular carcinoma development.
    Cheng H; Xue J; Yang S; Chen Y; Wang Y; Zhu Y; Wang X; Kuang D; Ruan Q; Duan Y; Wang G
    Oncotarget; 2017 Jul; 8(29):47984-47997. PubMed ID: 28624790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overexpression of microRNA-133b is associated with the increased survival of patients with hepatocellular carcinoma after curative hepatectomy: Involvement of the EGFR/PI3K/Akt/mTOR signaling pathway.
    Wang X; Zeng J; Wang L; Zhang X; Liu Z; Zhang H; Dong J
    Oncol Rep; 2017 Jul; 38(1):141-150. PubMed ID: 28586051
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MicroRNA-449a suppresses hepatocellular carcinoma cell growth via G1 phase arrest and the HGF/MET c-Met pathway.
    Cheng J; Wu LM; Deng XS; Wu J; Lv Z; Zhao HF; Yang Z; Ni Y
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):336-344. PubMed ID: 30108016
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MicroRNA-1207-5p inhibits hepatocellular carcinoma cell growth and invasion through the fatty acid synthase-mediated Akt/mTOR signalling pathway.
    Zhao G; Dong L; Shi H; Li H; Lu X; Guo X; Wang J
    Oncol Rep; 2016 Sep; 36(3):1709-16. PubMed ID: 27461404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MicroRNA-188-5p suppresses tumor cell proliferation and metastasis by directly targeting FGF5 in hepatocellular carcinoma.
    Fang F; Chang RM; Yu L; Lei X; Xiao S; Yang H; Yang LY
    J Hepatol; 2015 Oct; 63(4):874-85. PubMed ID: 25998163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification and interaction analysis of key genes and microRNAs in hepatocellular carcinoma by bioinformatics analysis.
    Mou T; Zhu D; Wei X; Li T; Zheng D; Pu J; Guo Z; Wu Z
    World J Surg Oncol; 2017 Mar; 15(1):63. PubMed ID: 28302149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. miR-22 targets YWHAZ to inhibit metastasis of hepatocellular carcinoma and its down-regulation predicts a poor survival.
    Chen M; Hu W; Xiong CL; Qu Z; Yin CQ; Wang YH; Luo CL; Guan Q; Yuan CH; Wang FB
    Oncotarget; 2016 Dec; 7(49):80751-80764. PubMed ID: 27811373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma.
    Fang Y; Xue JL; Shen Q; Chen J; Tian L
    Hepatology; 2012 Jun; 55(6):1852-62. PubMed ID: 22234835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MicroRNA‑9‑5p downregulates Klf4 and influences the progression of hepatocellular carcinoma via the AKT signaling pathway.
    Dong X; Wang F; Xue Y; Lin Z; Song W; Yang N; Li Q
    Int J Mol Med; 2019 Mar; 43(3):1417-1429. PubMed ID: 30664155
    [TBL] [Abstract][Full Text] [Related]  

  • 31. miR-505 enhances doxorubicin-induced cytotoxicity in hepatocellular carcinoma through repressing the Akt pathway by directly targeting HMGB1.
    Lu L; Zhang D; Xu Y; Bai G; Lv Y; Liang J
    Biomed Pharmacother; 2018 Aug; 104():613-621. PubMed ID: 29803174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Upregulation of UBE2Q1 via gene copy number gain in hepatocellular carcinoma promotes cancer progression through β-catenin-EGFR-PI3K-Akt-mTOR signaling pathway.
    Zhang B; Deng C; Wang L; Zhou F; Zhang S; Kang W; Zhan P; Chen J; Shen S; Guo H; Zhang M; Wang Y; Zhang F; Zhang W; Xiao J; Kong B; Friess H; Zhuge Y; Yan H; Zou X
    Mol Carcinog; 2018 Feb; 57(2):201-215. PubMed ID: 29027712
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNA-424 inhibits Akt3/E2F3 axis and tumor growth in hepatocellular carcinoma.
    Yang H; Zheng W; Shuai X; Chang RM; Yu L; Fang F; Yang LY
    Oncotarget; 2015 Sep; 6(29):27736-50. PubMed ID: 26315541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MicroRNA‑144 suppresses tumorigenesis of hepatocellular carcinoma by targeting AKT3.
    Ma Y; She XG; Ming YZ; Wan QQ; Ye QF
    Mol Med Rep; 2015 Feb; 11(2):1378-83. PubMed ID: 25370363
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functional microRNA high throughput screening reveals miR-9 as a central regulator of liver oncogenesis by affecting the PPARA-CDH1 pathway.
    Drakaki A; Hatziapostolou M; Polytarchou C; Vorvis C; Poultsides GA; Souglakos J; Georgoulias V; Iliopoulos D
    BMC Cancer; 2015 Jul; 15():542. PubMed ID: 26206264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional lncRNA-miRNA-mRNA Networks in Response to Baicalein Treatment in Hepatocellular Carcinoma.
    Zhao X; Tang D; Chen X; Chen S; Wang C
    Biomed Res Int; 2021; 2021():8844261. PubMed ID: 33511213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. microRNA-206 prevents hepatocellular carcinoma growth and metastasis via down-regulating CREB5 and inhibiting the PI3K/AKT signaling pathway.
    Chi Y; Gong Z; Xin H; Wang Z; Liu Z
    Cell Cycle; 2022 Dec; 21(24):2651-2663. PubMed ID: 36003063
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MicroRNA-451: epithelial-mesenchymal transition inhibitor and prognostic biomarker of hepatocelluar carcinoma.
    Huang JY; Zhang K; Chen DQ; Chen J; Feng B; Song H; Chen Y; Zhu Z; Lu L; De W; Wang R; Chen LB
    Oncotarget; 2015 Jul; 6(21):18613-30. PubMed ID: 26164082
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MicroRNA-155 promotes tumor growth of human hepatocellular carcinoma by targeting ARID2.
    Zhang L; Wang W; Li X; He S; Yao J; Wang X; Zhang D; Sun X
    Int J Oncol; 2016 Jun; 48(6):2425-34. PubMed ID: 27035278
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MiR-6875-3p promotes the proliferation, invasion and metastasis of hepatocellular carcinoma via BTG2/FAK/Akt pathway.
    Xie Y; Du J; Liu Z; Zhang D; Yao X; Yang Y
    J Exp Clin Cancer Res; 2019 Jan; 38(1):7. PubMed ID: 30621734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 135.